Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) - Current Issue

Background: Omalizumab is a monoclonal anti-IgE antibody approved for the treatment of severe allergic asthma. There is increasing evidence in the literature of its usefulness in other allergic conditions such as chronic urticaria and nasal polyposis. Methods: Here in, we report a prospective case series of 52 adult patients in a tertiary university hospital, Allergy and Immunology Clinic: 36 with severe asthma, among them 6 wi Read More